Mount Sinai Tisch Cancer Center has performed the first robotic nipple-sparing mastectomy in New York City. The procedure, which used Intuitive Surgical's da Vinci Single-Port (SP) robotic system following U.S. Food and Drug Administration (FDA) clearance earlier this year, marks a milestone in breast surgery and introduces an emerging minimally invasive capability at Mount Sinai.
On Wednesday, October 28, during Breast Cancer Awareness Month, Tristen S. Park, MD, a breast surgical oncologist and Associate Professor of Surgery at the Icahn School of Medicine at Mount Sinai, performed a bilateral robotic nipple-sparing mastectomy on a 44-year-old patient with a BRCA1 genetic mutation. Alice Yao, MD, Associate Professor of Surgery (Plastic and Reconstructive Surgery), performed immediate implant-based breast reconstruction. The patient recovered well and returned home the day after surgery.
The robotic system enables surgeons to remove breast tissue through an approximately 3.5-centimeter incision below the armpit while preserving the breast skin and nipple-areolar complex. The incision is away from the breast itself. Combined with immediate reconstruction, this approach aims to preserve the breast's external appearance without traditional mastectomy incisions.
The successful completion of this procedure is an exciting milestone for Mount Sinai and reflects the extraordinary dedication and collaboration of our surgical teams. Congratulations to Tristen Park on a tremendous achievement and thank you to everyone in the operating room for your invaluable contributions and partnership. This is an important step in advancing innovative, patient-centered breast cancer care and exemplifies Mount Sinai breast surgery and plastic surgical teams' commitment to delivering the highest and most advanced level of breast cancer care on all fronts."
Elisa Port, MD, Chief of Breast Surgery, Mount Sinai and Director of the Dubin Breast Center, The Mount Sinai Hospital
Nipple-sparing mastectomy may be an option for selected patients undergoing surgery for breast cancer or to reduce their risk of developing it. For people with BRCA1 or BRCA2 mutations, preventive mastectomy can significantly reduce breast cancer risk. Preserving the nipple and breast skin may also support body image and emotional well-being after surgery.
"Robotic-assisted nipple-sparing mastectomy can offer substantially improved precision and visualization for the surgeon. Published data thus far have demonstrated promising outcomes in preserving sensation, as well as patient satisfaction and quality-of-life measures compared with traditional approaches," said Dr. Park. "I am also deeply grateful to our Chief of Breast Surgery, Dr. Port, our hospital and operating room leadership, and our exceptional surgical team for their support and dedication throughout this effort."
Dr. Park began exploring robotic breast surgery in 2022, when she traveled to South Korea as a visiting professor and observed Professor Han-Byoel Lee, MD, PhD, and his team perform robotic breast surgery at Seoul National University. She subsequently pursued mentorship and training with robotic breast surgeons in France, South Korea, Taiwan, and the United States.
As of the surgery on October 28, 2026, Dr. Park was one of the first breast surgeons credentialed to perform this procedure with this robotic system in the United States and the first one in New York City. She also serves on the American Society of Breast Surgeons' Robotic Surgery Task Force, which is working to develop national guidelines and best practices, establish a nationwide robotic breast surgery registry, and advance surgeon education.
This procedure reflects Mount Sinai Tisch Cancer Center's commitment to advancing breast cancer care through surgical innovation, multidisciplinary collaboration, and treatment tailored to each patient.